摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3aR,4S,6R,6aS)-4-hydroxy-6-methoxy-5,5-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-2-one | 206185-26-4

中文名称
——
中文别名
——
英文名称
(3aR,4S,6R,6aS)-4-hydroxy-6-methoxy-5,5-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-2-one
英文别名
(3aS,4R,6S,6aR)-6-hydroxy-4-methoxy-5,5-dimethyl-3a,4,6,6a-tetrahydrocyclopenta[d][1,3]dioxol-2-one
(3aR,4S,6R,6aS)-4-hydroxy-6-methoxy-5,5-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-2-one化学式
CAS
206185-26-4
化学式
C9H14O5
mdl
——
分子量
202.207
InChiKey
BCYPHTUNOFLAHK-WNJXEPBRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.89
  • 拓扑面积:
    65
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • Enantiospecific Total Synthesis of (−)-D-Noviose
    作者:Wolf Matthias Pankau、Wolfgang Kreiser
    DOI:10.1002/(sici)1522-2675(19981111)81:11<1997::aid-hlca1997>3.0.co;2-v
    日期:1998.11.11
    (-)-D-Noviose ((-)-22), a rare sugar, was synthesized starting from the optically active building block (-)1 in seven steps. The first step of this route, the introduction of a methyl-ether group under Lewis-acidic conditions, left the acetoxy group untouched and thereby preserved the absolute configuration in the product 2 (Scheme 2). Next, the double bond of methyl ether 2 was cis-dihydroxylated leading selectively to 3. After saponification of the acetoxy group of 3 the two vicinal cis OH groups of 17 were selectively protected as the cyclic carbonate 18 (Scheme 4). This kind of protection was essential to achieve the proper regioselectivity in the Baeyer-Villiger rearrangement of the cyclopentanone derivative 19 that was obtained after oxidation of the remaining OH group of 18. Lactone 20 was the major product of this rearrangement. Final reduction to the corresponding lactol (cyclic hemiacetal) with diisobutylaluminium hydride (DIBAH) at low temperature was accompanied by reductive cleavage of the protecting cyclic carbonate moiety thereby leading directly to (-)-D-noviose ((-)-22).
    (-)-D-向日葵糖((-)-22)是一种稀有糖,从光学活性结构单元(-)1出发,经七步合成。该路线的第一步是在路易斯酸条件下引入甲基醚基团,该步骤未触碰乙酰氧基,从而保留了产物2中的绝对构型(方案2)。接下来,甲基醚2的双键进行顺式二羟化,选择性地得到3。在对3的乙酰氧基进行皂化后,3中邻近的两个顺式OH基团被选择性地保护为环状碳酸酯18(方案4)。这种保护方式对于后续环戊酮生物19的贝叶斯-维尔格重排反应中获得合适的区域选择性至关重要,而19是由18剩余的OH基团氧化得到的。贝叶斯-维尔格重排的主要产物是环状酯20。最后,使用二异丁基氢化物(DIBAH)在低温下将环状酯20还原为相应的环状半缩醛乳糖醇),同时伴随环状碳酸酯保护基团的还原裂解,从而直接得到(-)-D-向日葵糖((-)-22)。
  • Enantioselective total synthesis of (−)-D-noviose
    作者:W.Matthias Pankau、Wolfgang Kreiser
    DOI:10.1016/s0040-4039(98)00295-0
    日期:1998.4
    Noviose (1), the sugar moiety of the antibiotic Novobiocin(1), has been synthesized enantioselectively from the readily available(2) chiral building block 2 in seven steps. (C) 1998 Elsevier Science Ltd. All rights reserved.
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)